Merck & Co., Inc. (MRK) Shares Sold by Huber Financial Advisors LLC

Share on StockTwits

Huber Financial Advisors LLC cut its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 1.7% in the 4th quarter, Holdings Channel reports. The firm owned 8,626 shares of the company’s stock after selling 151 shares during the period. Huber Financial Advisors LLC’s holdings in Merck & Co., Inc. were worth $659,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. InterOcean Capital LLC lifted its holdings in shares of Merck & Co., Inc. by 28.2% in the 4th quarter. InterOcean Capital LLC now owns 4,994 shares of the company’s stock worth $382,000 after acquiring an additional 1,098 shares during the last quarter. LexAurum Advisors LLC lifted its holdings in shares of Merck & Co., Inc. by 2.9% in the 4th quarter. LexAurum Advisors LLC now owns 6,663 shares of the company’s stock worth $509,000 after acquiring an additional 186 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in shares of Merck & Co., Inc. by 136.1% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 695,596 shares of the company’s stock worth $53,150,000 after acquiring an additional 400,917 shares during the last quarter. IMS Capital Management lifted its holdings in shares of Merck & Co., Inc. by 27.1% in the 4th quarter. IMS Capital Management now owns 14,194 shares of the company’s stock worth $1,085,000 after acquiring an additional 3,029 shares during the last quarter. Finally, Stevens First Principles Investment Advisors lifted its holdings in shares of Merck & Co., Inc. by 29.9% in the 4th quarter. Stevens First Principles Investment Advisors now owns 3,329 shares of the company’s stock worth $254,000 after acquiring an additional 767 shares during the last quarter. Institutional investors and hedge funds own 73.39% of the company’s stock.

Shares of NYSE MRK opened at $78.53 on Tuesday. The company has a current ratio of 1.17, a quick ratio of 0.92 and a debt-to-equity ratio of 0.74. Merck & Co., Inc. has a 52 week low of $56.26 and a 52 week high of $83.85. The firm has a market capitalization of $214.16 billion, a P/E ratio of 18.09, a PEG ratio of 1.94 and a beta of 0.63.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, February 1st. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.03 by $0.01. Merck & Co., Inc. had a net margin of 14.71% and a return on equity of 36.83%. The company had revenue of $11 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same period in the previous year, the firm earned $0.98 earnings per share. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. On average, analysts anticipate that Merck & Co., Inc. will post 4.65 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 5th. Shareholders of record on Friday, March 15th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.80%. The ex-dividend date was Thursday, March 14th. Merck & Co., Inc.’s payout ratio is currently 50.69%.

A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $93.00 price objective for the company in a report on Monday, April 1st. Cantor Fitzgerald restated a “buy” rating and issued a $95.00 price objective on shares of Merck & Co., Inc. in a report on Friday, March 29th. Argus lifted their target price on shares of Merck & Co., Inc. to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, February 20th. BMO Capital Markets reaffirmed a “hold” rating on shares of Merck & Co., Inc. in a research note on Tuesday, February 19th. Finally, Citigroup set a $65.00 target price on shares of Merck & Co., Inc. and gave the stock a “hold” rating in a research note on Thursday, December 20th. Five research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Merck & Co., Inc. currently has a consensus rating of “Buy” and a consensus target price of $77.83.

In other Merck & Co., Inc. news, CEO Kenneth C. Frazier sold 92,913 shares of the business’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $80.03, for a total transaction of $7,435,827.39. Following the transaction, the chief executive officer now directly owns 784,863 shares of the company’s stock, valued at approximately $62,812,585.89. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Merck & Co., Inc. acquired 4,121,683 shares of Merck & Co., Inc. stock in a transaction on Monday, April 8th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $65,946,928.00. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 1,094,632 shares of company stock worth $87,840,652. Insiders own 0.32% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Merck & Co., Inc. (MRK) Shares Sold by Huber Financial Advisors LLC” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4296132/merck-co-inc-mrk-shares-sold-by-huber-financial-advisors-llc.html.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Gross Domestic Product (GDP)

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Obsidian Trading Down 30.4% This Week
Obsidian Trading Down 30.4% This Week
Monolithic Power Systems  Lowered to “Hold” at BidaskClub
Monolithic Power Systems Lowered to “Hold” at BidaskClub
NPER  Achieves Market Capitalization of $200,708.00
NPER Achieves Market Capitalization of $200,708.00
Bausch Health Companies  Downgraded to “Sell” at ValuEngine
Bausch Health Companies Downgraded to “Sell” at ValuEngine
Innophos  Cut to “Sell” at BidaskClub
Innophos Cut to “Sell” at BidaskClub
Bed Bath & Beyond  Lowered to Sell at BidaskClub
Bed Bath & Beyond Lowered to Sell at BidaskClub


© 2006-2019 Ticker Report